NCT07172659View on ClinicalTrials.gov

Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

October 31, 2027

Conditions
Erythema Nodosum Leprosum
Interventions
DRUG

Dovramilast

Dovramilast

DRUG

Prednisolone

Standard of care

DRUG

Thalidomide

Standard of care (US only)

Trial Locations (6)

90007

University of Southern California, Los Angeles

98104

Harborview Medical Center, University of Washington, Seattle

Unknown

Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli, Abomey-Calavi

Chr de Divo, Divo

Universitas Gadjah Mada, Yogyakarta

Philippine General Hospital, University of the Philippines, Manila, Manila

All Listed Sponsors
lead

Medicines Development for Global Health

OTHER